glp-1 based therapeutics summit 2nd GLP-1-Based 2025 [04/29/25] Market Overview: GLP-1 Agonists and

Jones C, Obomanu E, Neely A, Byfield K, Ugwu C, Megiso M, et al

Counterfeit packaging often has subtle printing errors, slightly wrong colors, or missing security features

David Kessler, MD, explains why he believes visceral adiposity is the greatest public health failure of our lifetime

[DOI] [PMC free article] [PubMed] [Google Scholar] 87.Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, et al

Recent clinical trials further suggest that these agents may also have favourable effects on clinical outcomes in obese HFpEF patients

Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R., et al